Shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) traded up 2.5% during trading on Wednesday . The stock traded as high as $1.23 and last traded at $1.16. 265,021 shares changed hands during mid-day trading, an increase of 6% from the average session volume of 249,964 shares. The stock had previously closed at $1.19.

Several analysts have commented on the stock. HC Wainwright set a $6.00 price objective on shares of Eyegate Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Noble Financial reaffirmed a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Friday, May 19th.

The company’s market cap is $19.61 million. The company has a 50 day moving average of $1.13 and a 200 day moving average of $1.77.

An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. grew its stake in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 247,319 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,988 shares during the quarter. Vanguard Group Inc. owned about 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.99% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Eyegate Pharmaceuticals, Inc. (EYEG) Stock Price Up -2.5%” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.